Acuta Capital Partners buys $7.8 Million stake in IRIDEX Corporation (IRIX)

IRIDEX Corporation (IRIX) : Acuta Capital Partners scooped up 200,670 additional shares in IRIDEX Corporation during the most recent quarter end , the firm said in a disclosure report filed with the SEC on May 13, 2016. The investment management firm now holds a total of 657,670 shares of IRIDEX Corporation which is valued at $7.8 Million.IRIDEX Corporation makes up approximately 4.59% of Acuta Capital Partners’s portfolio.

Other Hedge Funds, Including , Mufg Americas Holdings Corp sold out all of its stake in IRIX during the most recent quarter. The investment firm sold 1,280 shares of IRIX which is valued $15,206.Drill Craig A reduced its stake in IRIX by selling 8,200 shares or 14.88% in the most recent quarter. The Hedge Fund company now holds 46,900 shares of IRIX which is valued at $557,172. IRIDEX Corporation makes up approx 1.39% of Drill Craig A’s portfolio.Stanley-laman Group Ltd. reduced its stake in IRIX by selling 8,835 shares or 28.66% in the most recent quarter. The Hedge Fund company now holds 21,987 shares of IRIX which is valued at $261,206. IRIDEX Corporation makes up approx 0.05% of Stanley-laman Group Ltd.’s portfolio.

IRIDEX Corporation closed down -0.14 points or -0.99% at $13.96 with 89,720 shares getting traded on Wednesday. Post opening the session at $14.1, the shares hit an intraday low of $13.74 and an intraday high of $14.7299 and the price fluctuated in this range throughout the day.Shares ended Wednesday session in Red.

IRIDEX Corporation is a provider of therapeutic based laser consoles delivery devices and consumable instrumentation used to treat sight-threatening eye diseases in ophthalmology. The Company’s ophthalmology products consist of laser consoles delivery devices and consumable instrumentation including laser probes. In addition the Company’s ophthalmology products are often used in vitrectomy procedures (used to treat proliferative diabetic retinopathy macular holes retinal tears and detachments) which are generally performed in the operating room and require a consumable single use intraocular laser probe (EndoProbe) to deliver light to the back of the eye together with other instrumentation. The Company offers ophthalmology treatments for a number of conditions such as Age-related Macular Degeneration Diabetic Retinopathy Proliferative Glaucoma Retinal Tears and Detachments Retinopathy of Prematurity Ocular Tumors and Macular Holes.

Leave a Reply

IRIDEX Corporation - Is it time to Sell?

Top Brokerage Firms are advising their investors on IRIDEX Corporation. Subscribe to MoneyFlowIndex.Org Pre-Market Alerts, You will be the first to know the street buzz.